J. Anton
Istituto Giannina Gaslini
25 Papers
41 Citations
J. Anton is an academic researcher from Istituto Giannina Gaslini. The author has contributed to research in topics: Arthritis & Canakinumab. The author has an hindex of 4, co-authored 23 publications.
Chat about Author
Papers
Efficacy and Safety of Canakinumab in Patients with Periodic Fever Syndromes (Colchicine-Resistant FMF, HIDS/MKD and TRAPS): Results from a Phase 3, Pivotal, Umbrella Trial
F De Benedetti,J. Anton,Eldad Ben-Chetrit,Inmaculada Calvo,J Frenkel,Marco Gattorno,Hal M Hoffman,Ozgur Kasapcopur,I Kone-Paut,H Lachmann,Michel Moutschen,S Ozen,Pierre Quartier,Anna Simon,Andrew Zeft,Karine Lheritier,A. Speziale,Guido Junge +17 more
- 01 Apr 2017
TL;DR: The safety and effectiveness of Canakinumab in patients with periodic fever syndromes (colchicine-resistant fmf, hids/mkd and traps): results from a phase 3, pivotal, umbrella trial F. De Benedetti Pediatric Rheumatology 2017, 15(Suppl 1):O1 is presented.
9
OP0215 Subcutaneous Abatacept in Patients with Polyarticular Juvenile Idiopathic Arthritis and Inadequate Response To Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Pharmacokinetics, Efficacy and Safety
N Ruperto,Daniel J. Lovell,Nikolay Tzaribachev,Gabriel Vega-Cornejo,Ingrid Louw,Alberto Berman,Inmaculada Calvo,Ruben Cuttica,G. Horneff,F. Avila-Zapata,J. Anton,Diego O Viola,Ivan Foeldvari,Vladimir Keltsev,Daniel J. Kingsbury,X. Li,Marleen Nys,R. Wong,S. Banerjee,Alberto Martini,Hermine I. Brunner +20 more
TL;DR: Robust efficacy was observed with SC ABA with no new safety concerns after 4M of treatment and the target therapeutic exposure for SC abatacept was achieved in pts aged 6–17 yrs with pJIA irrespective of weight group.
7
IL1RN Variation Influences both Disease Susceptibility and Response to Human Recombinant IL-1RA Therapy in Systemic Juvenile Idiopathic Arthritis
Arthur Vl,E Shuldiner,Elaine F. Remmers,Anne Hinks,A. Grom,Dirk Foell,A Martini,Marco Gattorno,S Ozen,S Prahalad,Andrew Zeft,John F. Bohnsack,Norman T. Ilowite,Elizabeth Mellins,R Russo,Claudio Arnaldo Len,Sara Marchesan Oliveira,Rsm Yeung,Alan M. Rosenberg,Lucy R. Wedderburn,J. Anton,J.-P. Haas,Angela Rösen-Wolff,K. Minden,Ann Marie Szymanski,Wendy Thomson,DL Kastner,P Woo,Michael J. Ombrello +28 more
- 02 Apr 2018
TL;DR: IL1RN was the only candidate locus associated with sJIA in the largest study population assembled to date, and implicated SNPs are among the strongest known determinants of IL1RN and IL1RA levels, linking low expression with increased sJia risk.
6
International PFAPA syndrome registry: cohort of 214 patients
Michael Hofer,Pascal Pillet,Stefan Berg,Riva Brik,Pavla Dolezalova,I Kone-Paut,J. Anton,Isabelle Touitou,Brigitte Bader-Meunier,Daniela Kaiser,Donato Rigante,Agnès Duquesne,Carine Wouters,Marco Gattorno +13 more
TL;DR: Pediatric Rheumatology of Suisse Romande, Lausanne – Geneva, Switzerland and Genoa, Italy.
5
Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data.
N Ruperto,Hermine I. Brunner,I Kone-Paut,Bo Magnusson,S Ozen,Flavio Sztajnbok,J. Anton,Judith Barash,F. Corona,Karine Lheritier,Corine Gaillez,A Martini,Daniel J. Lovell +12 more
TL;DR: Canakinumab (CAN), a selective, human, anti- interleukin-1β monoclonal antibody, has been shown to be efficacious in the treatment of SJIA.